Crispr Therapeutics shares tumble after significant earnings miss
WATERTOWN, Mass. - Disc Medicine, Inc. (NASDAQ:IRON), a $1.76 billion market cap biotechnology company with a "GOOD" financial health rating according to InvestingPro, presented data from its three clinical programs at the European Hematology Association (EHA) 2025 annual meeting in Milan, showing positive results across its pipeline of treatments for hematologic diseases.
The company highlighted long-term data from the HELIOS open-label extension study of bitopertin in erythropoietic protoporphyria (EPP). Results demonstrated sustained reductions in protoporphyrin IX levels, improvements in quality of life measures, and favorable liver biomarkers with up to two years of treatment. With a strong current ratio of 37.65 and more cash than debt on its balance sheet, Disc Medicine appears well-positioned to advance its New Drug Application for bitopertin in the second half of 2025 while continuing its confirmatory APOLLO trial in adults and adolescents with EPP.
For DISC-0974, the company presented longer-term data from its Phase 1b trial in myelofibrosis anemia, showing durable responses among major responders. Among non-transfusion dependent patients, 50% achieved a sustained hemoglobin increase of at least 1.5 g/dL, while 80% of low transfusion burden patients achieved transfusion independence over 16 weeks. The company’s Phase 2 RALLY-MF trial is ongoing with initial data expected in the second half of 2025.
Disc Medicine also shared updated results from its Phase 1 healthy volunteer study of DISC-3405, demonstrating the drug’s ability to produce sustained reductions in serum iron levels and meaningful changes in hematologic parameters. Based on these findings, the company has initiated a Phase 2 trial in polycythemia vera with results expected in 2026.
A separate iron pulse study of DISC-3405 showed the drug inhibited dietary iron uptake by 94% at day 2 and 68% at day 15 following treatment, supporting its potential in iron overload conditions.
The company will host a conference call to discuss these updates on Monday, June 16.
The information in this article is based on a press release statement from Disc Medicine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.